Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein

Abstract From the Canadian patent

16, Title NN-O217, Monoclonal Antibodies Against Activated Ras Proteins with Amino, Acid Mutations at Position 13 of the Protein Abstract, Monoclonal antibodies reactive with oncogenic and activated ras p21 proteins containing aspartic acid or valine at position 13 and unreactive with normal ras p21 proteins containing glycine at position 13. The antibodies are secreted by hybridomas obtained by immunizing mice with synthetic peptide corresponding in amino acid sequence to positions 5-19 of normal ras p21 proteins except, having aspartic acid or valine in place of glycine at position 13 and except for the addition of glycine at the amino terminal end of the peptide. The antibodies and …